Unrelated donor transplantation over the age of 55. Are we merely getting (b)older?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2007
   Trial
2. Prognostic factors and a novel scoring system for allogeneic hematopoietic stem cell transplantation in patients aged 70 years or older: a nationwide registry analysis in Japan.Bone marrow transplantation · 2026
   Article
3. Prolonged length of stay in high-risk patients undergoing allogeneic stem cell transplantation: a call to action for addressing healthcare challenges.Bone marrow transplantation · 2025
   Article
4. Turkish Hematologists’ Preferences for Related Donor Selection: Results of a Multicenter SurveyTurkish journal of haematology : official journal of Turkish Society of Haematology · 2024
   Article
5. Impact of age on hospitalization and outcomes post allogeneic hematopoietic cell transplantation outcome, a single center experience.Annals of hematology · 2023
   Article
6. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.Blood · 2017
   Article
7. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2009
   Article
8. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2008
   Article
9. Comorbidity and beyond: pre-transplant clinical assessment.Bone marrow transplantation · 2005
   Article

Corrections and comments

• Comment on
  Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning.2005

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as